Westend61 via Getty Images

Human Immunity to Cas9 Could Threaten CRISPR’s Future

New data shows that humans carry antibodies and even T-cells that target the Cas9 protein at the heart of CRISPR gene editing technology.

Published On 01/17/2018
1:52 PM EST
A A n early draft of a scientific paper about potential human immunity to the Cas9 protein caused the stock prices of companies developing CRISPR-based therapies to plummet last week as investors questioned whether the controversial genome-editing technology would ever be safe for humans.